Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Rhea-AI Summary

Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies through its Gene Circuit platform, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech.

The virtual presentation will be delivered by Timothy Lu, M.D., Ph.D., the company's Co-Founder and Chief Executive Officer, on Tuesday, August 19, 2025, at 2:20 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025.

Live video webcast on Tuesday, August 19th at 2:20 PM ET

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025.

Details for the presentation are as follows:

Date/Time: Tuesday, August 19, 2025 at 2:20 PM ET
Presenter: Timothy Lu, M.D., Ph.D., Senti Bio’s Co-Founder and Chief Executive Officer
Registration Link: HERE

About Webull Financial

Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.

About Senti Bio

Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.

Availability of Other Information About Senti Biosciences, Inc.

For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com

FAQ

When is Senti Biosciences (SNTI) presenting at the Webull Financial Corporate Connect Webinar?

Senti Biosciences will present on Tuesday, August 19, 2025 at 2:20 PM ET.

Who will be presenting for Senti Biosciences (SNTI) at the Webull Financial Webinar?

Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive Officer, will be presenting at the webinar.

What is Senti Biosciences' (SNTI) main technology focus?

Senti Biosciences focuses on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform.

What type of company is Senti Biosciences (SNTI)?

Senti Biosciences is a clinical-stage biotechnology company that develops next-generation cell and gene therapies.